cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Summit Therapeutics Inc
3 own
7 watching
Current Price
$1.65
$0.1
(6.45%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
348.3M
52-Week High
52-Week High
5.78
52-Week Low
52-Week Low
0.66
Average Volume
Average Volume
0.8M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization348.3M
icon52-Week High5.78
icon52-Week Low0.66
iconAverage Volume0.8M
iconDividend Yield--
iconP/E Ratio--
What does the Summit Therapeutics Inc do?
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company s lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Read More
How much money does Summit Therapeutics Inc make?
News & Events about Summit Therapeutics Inc.
Ticker Report
2 months ago
Summit Therapeutics Inc. (NASDAQ:SMMT Get Rating) CEO Mahkam Zanganeh bought 15,973,743 shares of the businesss stock in a transaction that occurred on Wednesday, March 8th. The stock was purchased at an average cost of $1.05 per share, with a total value of $16,772,430.15. Following ...
Business Wire
2 months ago
Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced the successful closing of its fully-subscribed $500 million rights offering. The rights offering resulted in the sale of approximately 476.2 million shares of the Companys common stock, par value $0.01, at a price...
Globe Newswire
3 months ago
PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit) on behalf of the Companys shareholders. The investigation seeks to determine whether Summit has issued false and misleading statements and/or failed to ...
Globe Newswire
3 months ago
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Feb. 08, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit) investors that the firm has initiated an investigation into whether Summit issued ...
Globe Newswire
4 months ago
PHILADELPHIA, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit) on behalf of the Companys investors. The investigation seeks to determine whether Summit issued false and misleading statements and/or failed to ...
Frequently Asked Questions
Frequently Asked Questions
What is Summit Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Summit Therapeutics Inc shares?
plus_minus_icon
How can I buy Summit Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Summit Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Summit Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Summit Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Summit Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Summit Therapeutics Inc?
plus_minus_icon
What percentage is Summit Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Summit Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.65
$0.1
(6.45%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
$2.50
$0.00 (0.00 %)
Telesis Bio Inc
Telesis Bio Inc
$1.85
$-0.07 (-3.65 %)
MARINUS PHARMACEUTICALS INC
MARINUS PHARMACEUTICALS INC
$7.06
$0.03 (0.43 %)
TREDEGAR CORP
TREDEGAR CORP
$7.27
$-0.03 (-0.41 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
$2.50
$0.00 (0.00 %)
Telesis Bio Inc
Telesis Bio Inc
$1.85
$-0.07 (-3.65 %)
MARINUS PHARMACEUTICALS INC
MARINUS PHARMACEUTICALS INC
$7.06
$0.03 (0.43 %)
TREDEGAR CORP
TREDEGAR CORP
$7.27
$-0.03 (-0.41 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00